Global Wound Care Congress

Biography

Brian Peskin, BSEE-MIT (1979), is a theoretical research scientist specializing in lipids‐based pharmacognosy, and CEO of Peskin Pharmaceuticals. His research focuses specifically on physiologically targeted essential fatty acids (EFAs) and their eicosanoid metabolites. Being a translational science expert with a long-term interest in diabetes and its underlying pathophysiology, extensive work in oncology and cardiology preceeded his applications into diabetic foot ulcers. His work is focused on pathways maximizing oxygen delivery and blood flow to the human cell and maximizing tissue functionality. Focus is on supporting and optimizing the patient's natural physiologic processes—not blocking or impeding metabolic pathways.

Research Interest

His research focuses specifically on physiologically targeted essential fatty acids (EFAs) and their eicosanoid metabolites. Being a translational science expert with a long-term interest in diabetes and its underlying pathophysiology, extensive work in oncology and cardiology preceeded his applications into diabetic foot ulcers/wounds.